TCM
SAGE icon

Teza Capital Management’s Sage Therapeutics SAGE Stock Holding History

Teza Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,589
Closed -$62.9K – 570
2024
Q4 		$62.9K Sell
11,589
-2,180
-16% -$13.3K 0.01% 464
2024
Q3 		$99.4K Buy
13,769
+1,592
+13% +$14.6K 0.01% 571
2024
Q2 		$132K Buy
+12,177
New +$156K 0.02% 544
2021
Q3 		– Sell
-11,562
Closed -$657K – 560
2021
Q2 		$657K Buy
11,562
+6,400
+124% +$452K 0.11% 253
2021
Q1 		$386K Buy
+5,162
New +$423K 0.08% 327
2020
Q4 		– Sell
-5,254
Closed -$321K – 418
2020
Q3 		$321K Sell
5,254
-10,258
-66% -$520K 0.19% 196
2020
Q2 		$645K Buy
+15,512
New +$563K 0.14% 224

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Teza Capital Management's SAGE Position: Q1 2025 in Review

Teza Capital Management sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 11,589 shares — an estimated $62.9K sold.

Teza Capital Management first reported a position in SAGE in Q2 2020 and held it in 7 quarters. The position peaked at $657K in Q2 2021. 198 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

  • Teza Capital Management reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Teza Capital Management sold 11,589 Sage Therapeutics shares in Q1 2025, an estimated $62.9K.
  • Teza Capital Management first reported a position in Sage Therapeutics in Q2 2020 and held it in 7 quarters.
  • Teza Capital Management's Sage Therapeutics position peaked at $657K in Q2 2021.
  • 198 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Teza Capital Management's 13F filing for Q1 2025, filed 15 May 2025.